Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of IPI-926 versus placebo in advanced chondrosarcoma
NL-OMON38109Phase 2Active, not recruiting
- Sponsor
- Infinity Pharmaceuticals, Inc.
- Start
- Aug 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chondrosarcoma comparing IPI-926, Placebo and Open-label IPI-926 after placebo progression (3 arms). Primary endpoints: Progression-free survival and Safety. Started Aug 2011; status: active, not recruiting.
02
Drugs
patidegib
03
Conditions
chondrosarcoma
Beyond the preview
Go deeper on NL-OMON38109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38109.